Mars B. van ’t Veer

Author

Mars B. van ’t Veer

Rotterdam University of Applied Sciences

Also Known As

M B van 't Veer, M B van ‘t Veer, M B. van 't Veer, M. B. Van 'T Veer, M. B. Van 't Veer, M. B. van 't Veer, M.B. Van 't Veer, M.B. van 't Veer, M.B. van ‘t Veer, M.B. van ’t Veer

Publications

2.4K

Citations

H-Index

Concepts

All Affiliations

Rotterdam University of Applied Sciences Erasmus MC The Netherlands Cancer Institute Erasmus MC Cancer Institute Amsterdam UMC Location University of Amsterdam

About

Mars B. van ’t Veer is an author at Rotterdam University of Applied Sciences specializing in medicine, hematology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	14	476
2	Health Sciences	6	6	157
3	Cell Biology	4	4	50
4	Allergy	1	1	13
5	Cellular Therapies	1	1	59

Mars B. van ’t Veer

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
Late cardiotoxicity after treatment for Hodgkin lymphoma Berthe M.P. Aleman, Alexandra W. van den Belt‐Dusebout, Marie L. De Bruin, Blood	2006	753
Involved-Field Radiotherapy for Advanced Hodgkin's Lymphoma Berthe M.P. Aleman, John Raemaekers, Umberto Tirelli, New England Journal of Medicine	2003	306
Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison Jan J. Cornelissen, Bronno van der Holt, Gregor Verhoef, Blood	2008	179
Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial Edo Vellenga, Wim L.J. van Putten, Mars B. van ’t Veer, Blood	2007	165
Roles of Radiation Dose and Chemotherapy in the Etiology of Stomach Cancer as a Second Malignancy Alexandra W. van den Belt‐Dusebout, Berthe M.P. Aleman, Gijs Besseling, International Journal of Radiation OncologyBiologyPhysics Surgical OncologyStomach CancerSecond MalignancyRadiation TherapyGastrointestinal Oncology	2009	98
A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma Franck Morschhauser, John F. Seymour, Hanneke C. Kluin‐Nelemans, Annals of Oncology Hematological MalignancyLymphoid NeoplasiaMedicineMalignant Blood DisorderImmunology	2007	97
Malignant mesothelioma after radiation treatment for Hodgkin lymphoma Marie L. De Bruin, Jacobus A. Burgers, Paul Baas, Blood	2009	84
High resolution melting analysis for detection of <i>BRAF</i> exon 15 mutations in hairy cell leukaemia and other lymphoid malignancies Elaine Boyd, Anthony J. Bench, Mars B. van ’t Veer, British Journal of Haematology High ResolutionMixed-phenotype Acute LeukemiaPathologyHairy Cell LeukaemiaDermatology	2011	77
Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma Gustaaf W. van Imhoff, Bronno van der Holt, Marius MacKenzie, Leukemia Lymphoid NeoplasiaCell TherapyTransplantationMarrow TransplantationStem Cell Transplantation	2005	59
Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL Christian H. Geisler, Mars B. van ’t Veer, Jesper Jurlander, Blood	2014	52

Page 1